Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Localized lidocaine injection into the middle meningeal artery for chronic migraine relief

Official title: Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment: A Randomized, Double-Blinded, Parallel Phase 2 Clinical Trial

Run by Cooper Norcross Health · NCT07361549 · Data updated 2026-11-12

This phase 2 trial tests whether injecting lidocaine into brain arteries can reduce chronic migraine headaches in adults.

More Headache trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment80 (estimated)
SponsorCooper Norcross Health
Academic / other
Locations1 site (Camden, New Jersey)
StatusRecruiting
StartedSeptember 9, 2026
Main results expectedDecember 2030
Study endsJuly 2031
Registry record updatedOctober 1, 2026
Trial IDNCT07361549 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with chronic migraine who are referred for diagnostic cerebral angiography and able to provide informed consent.

Probably not a fit

Patients with certain safety exclusions or without response to the intervention may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with chronic migraine who have not found relief with standard treatments will receive lidocaine injections into two brain arteries during diagnostic angiography. The study compares lidocaine to saline to see if the approach can lessen headache frequency or severity. Researchers will monitor safety and collect data on headache impact and potential adverse effects. Participation requires informed consent and adherence to safety criteria, including assessments for intracranial pathology. The trial is led by Daniel A. Tonetti, MD, with SNIS Foundation and Stryker Neurovascular collaborators at Cooper University Health Care in Camden, NJ.

Why it matters

Potential benefit: If successful, patients may experience fewer or less severe migraines with a targeted, potentially durable relief strategy.

How similar studies have gone: Prior studies in similar approaches have shown mixed results; this represents a targeted, neurovascular delivery method that is relatively novel in this context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or above
* Diagnosis of chronic migraine
* Referred for diagnostic cerebral angiography to screen for intracranial pathology
* Written informed consent able to be obtained from subject

Exclusion Criteria:

* Baseline HIT-6 score less than 50
* Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
* Concomitant intracranial pathology (eg, intracranial malignancy)
* Known hypersensitivity and/or contraindication to lidocaine or local anesthetics of the amide type
* Taking chronic medications that, when co-administered with lidocaine and other local anesthetics, are at increased risk of developing methemoglobinemia (nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, acetaminophen, metoclopramide, quinine, sulfasalazine)
* Known contraindications for angiography (eg, ESRD not requiring hemodialysis). Patients with contrast allergy with be premeditated with diphenhydramine and steroids.
* Contraindication to anesthetic agents used for conscious sedation/monitored anesthesia care (MAC)
* Concurrent participation in another research protocol for investigation of an experimental therapy
* Per DSA imaging, presence of a cerebrovascular pathology known to cause headache (eg, arteriovenous malformation, dural arteriovenous fistula)
* Per DSA imaging, presence of anastomosis or anatomical variation (eg, branches of middle meningeal artery) that could lead to increased procedural risk
* Per DSA imaging, lack of endovascular access to either middle meningeal artery, or origin of the middle meningeal artery other than from the external carotid artery
* Known or suspected inability to adhere to study protocol or protocol requirements, as per discretion of the Investigator or treating provider

Where it's running

  • Cooper University Health Care
    Camden, New Jersey, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.